Having co-morbid cardiovascular disease at time of cancer diagnosis: Already one step behind when it comes to HRQoL?

D. Schoormans*, O. Husson, S. Oerlemans, N.P.M. Ezendam, F. Mols

*Corresponding author for this work

Research output: Contribution to journalArticleScientificpeer-review

Abstract

Background
The relation between cardiovascular disease (CVD) present at the time of cancer diagnosis and Health-Related Quality of Life (HRQoL) assessed years after cancer diagnosis has – to our knowledge – not been studied. The objective is, therefore, to examine the relation between co-morbid CVD at cancer diagnosis and HRQoL among cancer survivors diagnosed with colorectal, thyroid, prostate, endometrium, ovarian cancer, melanoma, (non-)Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), or multiple myeloma (MM) in an exploratory population-based cross-sectional study.

Material and methods
Analyses were performed on combined data sets from the PROFILES and Netherlands Cancer Registry (NCR). Data on co-morbid CVD at cancer diagnosis was extracted from the NCR. HRQoL was measured via PROFILES at a median of 4.6 years after cancer diagnosis. General Linear Model Analyses were run for the total group of cancer survivors and for each malignancy.

Results
In total, 5930 cancer survivors (2281 colorectal, 280 thyroid, 1054 prostate, 177 endometrium, 389 ovarian cancer, 212 melanoma, 874 non-Hodgkin and 194 Hodgkin lymphoma, 242 CLL, and 227 MM survivors) were included. For the total group, survivors who had a CVD at cancer diagnosis (n = 1441, 23.4%) reported statistically significant and clinically important lower scores on global QoL and physical functioning and higher scores for dyspnea (p < .05) compared to those without CVD. Co-morbid CVD at cancer diagnosis was negatively related to global QoL, the five functional scales and the symptoms fatigue and dyspnea across most malignancies (i.e., colorectal, and prostate cancer, non-Hodgkin lymphoma, ovarium cancer, melanoma, and CLL). No significant relations were found among thyroid and endometrium cancer, Hodgkin lymphoma and MM survivors, likely due to small numbers.

Conclusion
In conclusion, co-morbid CVD at cancer diagnosis was negatively related to HRQoL, especially to global QoL, physical and role functioning, and the symptoms fatigue and dyspnea.
Original languageEnglish
Pages (from-to)1684-1691
JournalActa Oncologica
Volume58
Issue number12
DOIs
Publication statusPublished - 2019

Fingerprint

Neoplasms
Survivors
B-Cell Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma
Melanoma
Endometrial Neoplasms
Hodgkin Disease
Netherlands
Ovarian Neoplasms
Endometrium
Linear Models
Cross-Sectional Studies

Keywords

  • AGE
  • CARDIOTOXICITY
  • COMORBIDITY
  • IMPACT
  • LONG-TERM
  • OLDER
  • QLQ-C30
  • QUALITY-OF-LIFE
  • QUESTIONNAIRE
  • SURVIVORS

Cite this

@article{b728b8a59d12429c89ab4bdd45b0325e,
title = "Having co-morbid cardiovascular disease at time of cancer diagnosis: Already one step behind when it comes to HRQoL?",
abstract = "BackgroundThe relation between cardiovascular disease (CVD) present at the time of cancer diagnosis and Health-Related Quality of Life (HRQoL) assessed years after cancer diagnosis has – to our knowledge – not been studied. The objective is, therefore, to examine the relation between co-morbid CVD at cancer diagnosis and HRQoL among cancer survivors diagnosed with colorectal, thyroid, prostate, endometrium, ovarian cancer, melanoma, (non-)Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), or multiple myeloma (MM) in an exploratory population-based cross-sectional study.Material and methodsAnalyses were performed on combined data sets from the PROFILES and Netherlands Cancer Registry (NCR). Data on co-morbid CVD at cancer diagnosis was extracted from the NCR. HRQoL was measured via PROFILES at a median of 4.6 years after cancer diagnosis. General Linear Model Analyses were run for the total group of cancer survivors and for each malignancy.ResultsIn total, 5930 cancer survivors (2281 colorectal, 280 thyroid, 1054 prostate, 177 endometrium, 389 ovarian cancer, 212 melanoma, 874 non-Hodgkin and 194 Hodgkin lymphoma, 242 CLL, and 227 MM survivors) were included. For the total group, survivors who had a CVD at cancer diagnosis (n = 1441, 23.4{\%}) reported statistically significant and clinically important lower scores on global QoL and physical functioning and higher scores for dyspnea (p < .05) compared to those without CVD. Co-morbid CVD at cancer diagnosis was negatively related to global QoL, the five functional scales and the symptoms fatigue and dyspnea across most malignancies (i.e., colorectal, and prostate cancer, non-Hodgkin lymphoma, ovarium cancer, melanoma, and CLL). No significant relations were found among thyroid and endometrium cancer, Hodgkin lymphoma and MM survivors, likely due to small numbers.ConclusionIn conclusion, co-morbid CVD at cancer diagnosis was negatively related to HRQoL, especially to global QoL, physical and role functioning, and the symptoms fatigue and dyspnea.",
keywords = "AGE, CARDIOTOXICITY, COMORBIDITY, IMPACT, LONG-TERM, OLDER, QLQ-C30, QUALITY-OF-LIFE, QUESTIONNAIRE, SURVIVORS",
author = "D. Schoormans and O. Husson and S. Oerlemans and N.P.M. Ezendam and F. Mols",
year = "2019",
doi = "10.1080/0284186X.2019.1648861",
language = "English",
volume = "58",
pages = "1684--1691",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "TAYLOR & FRANCIS LTD",
number = "12",

}

Having co-morbid cardiovascular disease at time of cancer diagnosis : Already one step behind when it comes to HRQoL? / Schoormans, D.; Husson, O.; Oerlemans, S.; Ezendam, N.P.M.; Mols, F.

In: Acta Oncologica, Vol. 58, No. 12, 2019, p. 1684-1691.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Having co-morbid cardiovascular disease at time of cancer diagnosis

T2 - Already one step behind when it comes to HRQoL?

AU - Schoormans, D.

AU - Husson, O.

AU - Oerlemans, S.

AU - Ezendam, N.P.M.

AU - Mols, F.

PY - 2019

Y1 - 2019

N2 - BackgroundThe relation between cardiovascular disease (CVD) present at the time of cancer diagnosis and Health-Related Quality of Life (HRQoL) assessed years after cancer diagnosis has – to our knowledge – not been studied. The objective is, therefore, to examine the relation between co-morbid CVD at cancer diagnosis and HRQoL among cancer survivors diagnosed with colorectal, thyroid, prostate, endometrium, ovarian cancer, melanoma, (non-)Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), or multiple myeloma (MM) in an exploratory population-based cross-sectional study.Material and methodsAnalyses were performed on combined data sets from the PROFILES and Netherlands Cancer Registry (NCR). Data on co-morbid CVD at cancer diagnosis was extracted from the NCR. HRQoL was measured via PROFILES at a median of 4.6 years after cancer diagnosis. General Linear Model Analyses were run for the total group of cancer survivors and for each malignancy.ResultsIn total, 5930 cancer survivors (2281 colorectal, 280 thyroid, 1054 prostate, 177 endometrium, 389 ovarian cancer, 212 melanoma, 874 non-Hodgkin and 194 Hodgkin lymphoma, 242 CLL, and 227 MM survivors) were included. For the total group, survivors who had a CVD at cancer diagnosis (n = 1441, 23.4%) reported statistically significant and clinically important lower scores on global QoL and physical functioning and higher scores for dyspnea (p < .05) compared to those without CVD. Co-morbid CVD at cancer diagnosis was negatively related to global QoL, the five functional scales and the symptoms fatigue and dyspnea across most malignancies (i.e., colorectal, and prostate cancer, non-Hodgkin lymphoma, ovarium cancer, melanoma, and CLL). No significant relations were found among thyroid and endometrium cancer, Hodgkin lymphoma and MM survivors, likely due to small numbers.ConclusionIn conclusion, co-morbid CVD at cancer diagnosis was negatively related to HRQoL, especially to global QoL, physical and role functioning, and the symptoms fatigue and dyspnea.

AB - BackgroundThe relation between cardiovascular disease (CVD) present at the time of cancer diagnosis and Health-Related Quality of Life (HRQoL) assessed years after cancer diagnosis has – to our knowledge – not been studied. The objective is, therefore, to examine the relation between co-morbid CVD at cancer diagnosis and HRQoL among cancer survivors diagnosed with colorectal, thyroid, prostate, endometrium, ovarian cancer, melanoma, (non-)Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), or multiple myeloma (MM) in an exploratory population-based cross-sectional study.Material and methodsAnalyses were performed on combined data sets from the PROFILES and Netherlands Cancer Registry (NCR). Data on co-morbid CVD at cancer diagnosis was extracted from the NCR. HRQoL was measured via PROFILES at a median of 4.6 years after cancer diagnosis. General Linear Model Analyses were run for the total group of cancer survivors and for each malignancy.ResultsIn total, 5930 cancer survivors (2281 colorectal, 280 thyroid, 1054 prostate, 177 endometrium, 389 ovarian cancer, 212 melanoma, 874 non-Hodgkin and 194 Hodgkin lymphoma, 242 CLL, and 227 MM survivors) were included. For the total group, survivors who had a CVD at cancer diagnosis (n = 1441, 23.4%) reported statistically significant and clinically important lower scores on global QoL and physical functioning and higher scores for dyspnea (p < .05) compared to those without CVD. Co-morbid CVD at cancer diagnosis was negatively related to global QoL, the five functional scales and the symptoms fatigue and dyspnea across most malignancies (i.e., colorectal, and prostate cancer, non-Hodgkin lymphoma, ovarium cancer, melanoma, and CLL). No significant relations were found among thyroid and endometrium cancer, Hodgkin lymphoma and MM survivors, likely due to small numbers.ConclusionIn conclusion, co-morbid CVD at cancer diagnosis was negatively related to HRQoL, especially to global QoL, physical and role functioning, and the symptoms fatigue and dyspnea.

KW - AGE

KW - CARDIOTOXICITY

KW - COMORBIDITY

KW - IMPACT

KW - LONG-TERM

KW - OLDER

KW - QLQ-C30

KW - QUALITY-OF-LIFE

KW - QUESTIONNAIRE

KW - SURVIVORS

U2 - 10.1080/0284186X.2019.1648861

DO - 10.1080/0284186X.2019.1648861

M3 - Article

VL - 58

SP - 1684

EP - 1691

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 12

ER -